-- 週一，瑞穗證券將 CrowdStrike (CRWD) 的股票評級從“中性”上調至“跑贏大盤”，並將目標價從 490 美元上調至 520 美元，受此提振，CRWD 股價上漲約 1.6%。 成交量超過 140 萬股，而其每日平均成交量約為 420 萬股。
Price: $455.31, Change: $+7.18, Percent Change: +1.60%
Related Articles
Asia
Ora Banda Mining Appoints Chair-elect
Ora Banda Mining (ASX:OBM) has appointed John Richards as chair-elect, with plans for him to assume the role following the retirement of current Chair Peter Mansell at the company's annual general meeting in November, according to a Tuesday filing with the Australian bourse.Richards is currently non-executive chair of Sandfire Resources (ASX:SFR) and lead independent non-executive director of Sheffield Resources (ASX:SFX), the filing added.
$ASX:OBM$ASX:SFR$ASX:SFX
Research
Research Alert: Universal Health Services: Q1 Eps Tops Estimates
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:UHS delivered solid Q1 results, with adjusted EPS of $5.62 (up 16.1% Y/Y), $0.16 above consensus, while revenue grew 9.6% to $4.495B due to higher prices despite modest patient volumes. Same-facility acute care revenue increased 8.2% on flat adjusted admissions but 6.3% growth in revenue per admission, while behavioral health saw 1.2% admission growth and 7.3% revenue growth. We think the $835M Talkspace acquisition may expand UHS's virtual behavioral health capabilities and broaden payor mix. Management expects the deal to close in Q3. Operating cash flow improved 11.7% to $402M, and UHS repurchased $127.3M in stock, though adjusted EBITDA margin compressed 20 bps to 14.4% on higher operating expenses. We think behavioral health staffing challenges persist but expect the Talkspace integration to create growth opportunities.
$UHS
Research
Research Alert: Cls Q1: Blistering Fy 26 Guidance And Cpo Win Tempered By Capital Demands
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Q1 revenues of $4.05B (+53%) and adjusted EPS of $2.16 (+80%) both exceeded guidance on accelerating hyperscaler demand. Adjusted operating margin reached a record 8.0%, due to higher-value CCS offerings, which grew 76% to $3.24B, with segment margin expanding to 8.6%. The company secured a new CPO switch program with a hyperscaler customer expected to ramp in 2027, and we expect more color tomorrow. Management raised 2026 guidance to $19.0B revenue (from $17.0B) and $10.15 adjusted EPS (from $8.75), representing over $6.5B in revenue growth. Stronger growth is anticipated for 2027 based on improved customer visibility and new program wins. The company enlarged its balance sheet by upsizing its credit facility to $2.5B, with revolver capacity increased to $1.75B. FCF of $137.9M remained robust despite elevated capex of $218.4M to support capacity expansion. Share buybacks slowing, FCF guidance lagging, and a +50% month may be contributing to the after-hours selloff.
$CLS